<< Back to Results
GOG-0241 – A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent: Bevacizumab (NSC 704865, IND 7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC).
Clinical Trial Categories
- Hanjani Institute for Gynecologic Oncology at 215-885-0220
- Hanjani Institute for Gynecologic Oncology
The Rosenfeld Cancer Center
1200 Old York Rd, AMH - 1 Widener
Abington, PA 19001